rs2069837 — IL6

Intronic IL6 enhancer variant that regulates the anti-inflammatory gene GPNMB — the G allele lowers IL-6 signalling but is less common in long-lived individuals

See your personal result for IL6

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

The IL-6 Locus That Speaks to Longevity Through a Hidden Downstream Gene

Interleukin-6 is the cytokine most consistently elevated in older adults — a key driver of inflammaging11 inflammaging
the chronic low-grade inflammation that accumulates with age and underlies most age-related diseases, from atherosclerosis to Alzheimer's to type 2 diabetes. Within the IL6 gene lies a lesser-known intronic variant, rs2069837, whose effect on aging biology is not what you might expect: rather than directly changing IL-6 protein structure or promoter activity, it operates through a remarkable long-range genomic mechanism that reaches half a megabase away.

The Mechanism

rs2069837 sits in intron 2 of IL6, within an active enhancer region22 enhancer region
a stretch of non-coding DNA that can dramatically increase or decrease expression of target genes, often over large genomic distances. In 2019, researchers discovered that this variant doesn't primarily regulate IL6 itself — it regulates GPNMB33 GPNMB
glycoprotein NMB, an anti-inflammatory protein expressed in macrophages that dampens immune overactivation and promotes tissue resolution, located approximately 520 kilobases away on the same chromosome.

The mechanism operates through chromatin looping: CTCF44 CTCF
CCCTC-binding factor, a structural protein that creates physical contact points between distant genomic regions mediates a long-range interaction that brings the rs2069837 enhancer into physical contact with the GPNMB promoter. The A allele of rs2069837 preferentially recruits the MEF2-HDAC repressive complex55 MEF2-HDAC repressive complex
a protein complex that silences gene expression by compacting chromatin into a transcriptionally inactive state, suppressing GPNMB expression in monocyte-derived macrophages. The G allele disrupts this repressive recruitment, allowing GPNMB to be expressed normally. 66 Kong et al. Takayasu arteritis risk locus in IL6 represses the anti-inflammatory gene GPNMB through chromatin looping and recruiting MEF2-HDAC complex. Ann Rheum Dis, 2019

The downstream consequence is that A-allele carriers have lower macrophage GPNMB expression, which in turn alters the balance of IL-6 signalling — the A allele environment allows higher effective IL-6 activity because the anti-inflammatory brake (GPNMB) is partially removed. The G allele restores the brake.

The Evidence

Longevity GWAS: A genome-wide association study in Han Chinese centenarians77 genome-wide association study in Han Chinese centenarians
Zeng et al. Novel loci and pathways significantly associated with longevity. Scientific Reports, 2016 found rs2069837 reached genome-wide significance (P = 1.80 × 10⁻⁹) as a longevity locus, with the G allele significantly less frequent among centenarians than among middle-aged controls (OR = 0.61). This indicates the G allele is paradoxically the longevity-deleterious allele at this locus — those who live longest tend to carry more A alleles.

COVID-19 severity: The G allele's effect on GPNMB/IL-6 has an acute protective benefit in some inflammatory contexts. A GWAS of critical COVID-1988 GWAS of critical COVID-19
Gong et al. A genetic variant in IL-6 lowering its expression is protective for critical patients with COVID-19. Signal Transduct Target Ther, 2022 found G-allele carriers had dramatically lower risk of critical illness (OR = 0.41 in discovery cohort; OR = 0.49 in combined analysis, P = 4.64 × 10⁻¹⁶). The mechanism confirmed: the G allele decreased MEF2a binding and increased GPNMB expression, resulting in lower IL-6. The protective effect was stronger in males.

Hepatocellular carcinoma: In the context of chronic liver disease, the G allele confers risk rather than protection. A meta-analysis of 13 case-control studies99 meta-analysis of 13 case-control studies
Emami Aleagha et al. Association between IL-6 polymorphisms and HCC susceptibility. Clin Exp Hepatol, 2020 found the GG genotype associated with 2.25-fold elevated hepatocellular carcinoma risk (OR 2.25, 95% CI 1.18–4.29). This aligns with GPNMB's dual roles: GPNMB suppresses inflammatory tissue damage, but also blunts immune surveillance against tumour cells.

Alzheimer's disease: A Taiwanese case-control study1010 Taiwanese case-control study
Chen et al. Sequence variants of IL-6 are significantly associated with a decreased risk of late-onset Alzheimer's disease. J Neuroinflammation, 2012 analyzed IL6 haplotypes including rs2069837 in 266 AD cases and 444 controls. The strongest protective signal (adjusted OR = 0.65) came from a haplotype defined by rs1800796 and rs1524107 rather than rs2069837 directly. Hypertension significantly modified the association.

Practical Implications

This variant presents a genuine paradox: the G allele protects against acute inflammatory overreaction (severe COVID-19, autoimmune vasculitis) but is underrepresented among extreme long-livers in East Asian populations and associates with elevated hepatocellular carcinoma risk. This reflects GPNMB's dual nature — an anti-inflammatory signal that also dampens immune surveillance.

For AA homozygotes (the genotype of most centenarians), lower GPNMB expression maintains stronger macrophage inflammatory tone. This may be advantageous for cancer immune surveillance and, over decades, for the type of calibrated immune competence associated with exceptional longevity. However, the tradeoff is potentially higher IL-6 activity, making monitoring of inflammatory markers and IL-6-related disease risk more important.

For AG heterozygotes, intermediate GPNMB expression places them between the extremes. The clinical implications are modest and context-dependent.

For GG homozygotes (rare, ~1% of most populations), higher GPNMB suppresses IL-6 and may offer protection in acute inflammatory settings, but the rare homozygous state has been associated with elevated HCC risk and is uncommon in centenarians.

Interactions

rs2069837 exists within the broader IL6 gene context alongside the well-characterised promoter variant rs1800795 (-174G/C), which is in the GeneOps database under the fitness-body category. These two variants operate through distinct mechanisms and are not in strong linkage disequilibrium — rs1800795 affects promoter transcriptional activity directly, while rs2069837 acts through the distal GPNMB enhancer loop. Combined effects of rs1800795 (direct IL-6 production) and rs2069837 (GPNMB-mediated IL-6 modulation) on inflammaging have not been formally studied as a compound genotype. The interaction with IL-10 variants (particularly rs1800871) has been studied in epidemiological contexts, with IL6 rs2069837 × IL10 haplotype combinations showing region-specific effects on disease susceptibility.

Genotype Interpretations

What each possible genotype means for this variant.

AA High GPNMB Suppressors Normal

Common genotype — lower GPNMB, higher effective IL-6 tone, enriched in centenarians

The AA genotype at rs2069837 represents the ancestral, most prevalent allele combination worldwide. In the Han Chinese longevity GWAS (Zeng et al. 2016, PMID 26912274), AA-enriched individuals had a statistically significant advantage in reaching extreme old age (centenarian status) compared to G allele carriers, reaching genome-wide significance (P = 1.80 × 10⁻⁹).

The mechanistic interpretation is that lower macrophage GPNMB, maintained by the A allele's MEF2-HDAC recruitment, preserves macrophage pro-inflammatory capacity for immune surveillance. While this may increase susceptibility to acute inflammatory overreaction (as seen in COVID-19 severity studies), over a lifetime it may support the immune competence associated with exceptional longevity. The AA genotype also carries lower hepatocellular carcinoma risk in the limited studies available.

AG Intermediate

One protective G allele — intermediate GPNMB expression, mixed longevity profile

The AG genotype carries one copy of each allele: one chromosome drives MEF2-HDAC recruitment and GPNMB suppression; the other chromosome allows GPNMB expression. The net result is intermediate macrophage GPNMB levels, confirmed in functional studies (Kong et al. 2019, PMID 31315839) which showed AG macrophages had intermediate GPNMB expression between AA and GG.

In the COVID-19 protective effect study (Gong et al. 2022, PMID 35368020), G allele carriers (including AG) showed substantial protection against critical COVID-19 severity. The odds ratio for the combined G-carrier analysis was 0.49, indicating approximately half the risk of critical illness compared to AA. The protective effect was driven by the G allele's ability to reduce excessive IL-6 during acute infection.

In the Alzheimer's disease context, haplotypes carrying the G allele were associated with reduced LOAD risk (adjusted OR ~0.65) in Taiwanese subjects, particularly in ApoE ε4 non-carriers.

GG High GPNMB Expressors High Risk

Rare GG genotype — high GPNMB, lower IL-6 tone, elevated HCC risk, underrepresented in centenarians

GG homozygotes carry the maximally GPNMB-expressing genotype. Without MEF2-HDAC repression on either chromosome, macrophages produce higher levels of this anti-inflammatory protein. Mechanistically (Kong et al. 2019, PMID 31315839), this prevents the chromatin loop from forming an effective HDAC repressor complex at the GPNMB locus.

The COVID-19 study (Gong et al. 2022, PMID 35368020) confirmed that the G allele decreases IL-6 expression particularly in males, with GG males showing the lowest baseline IL-6. This reduction in IL-6 prevents the cytokine storm that drives critical COVID-19 illness. However, this same mechanism reduces the macrophage inflammatory capacity that, over decades, may impair immune surveillance against cancer and latent infections.

The hepatocellular carcinoma meta-analysis (PMID 33511285, 13 studies) found GG genotype OR = 2.25 for HCC risk. GPNMB's immunosuppressive role in the tumour microenvironment likely contributes — higher GPNMB blunts macrophage anti-tumour activity, particularly relevant in the chronically inflamed liver environment of hepatitis B/C carriers.

In the longevity GWAS, Han Chinese centenarians had significantly fewer G alleles than middle-aged controls (OR = 0.61), suggesting that over an 80+ year lifespan, lower GPNMB/higher immune tone (the AA genotype) is the winning strategy for extreme longevity.